男性非小细胞肺癌患者EGFR突变状态的识别:18F-FDG PET/CT与血清肿瘤标志物CYFRA21-1和SCC-Ag的作用
本研究分析了2019年10月至2022年3月间121例男性非小细胞肺癌(NSCLC)患者,所有患者治疗前接受18F-FDG PET/CT并检测8种血清肿瘤标志物(STMs)。结果显示39例(32.2%)存在EGFR突变,EGFR突变患者血清CYFRA21-1(2.65 vs 4.01,P=0.002)和SCC-Ag(0.67 vs 1.05,P=0.006)浓度较野生型患者低,低pSUVmax(<8.75)、低SCC-Ag(<0.79 ng/mL)和低CYFRA21-1(<2.91 ng/mL)与EGFR突变显著相关,三者联合的ROC曲线下面积为0.754,高于各单独指标。
要点
- 男性NSCLC患者中EGFR突变率为32.2%(39/121)。
- EGFR突变患者血清CYFRA21-1和SCC-Ag浓度显著低于野生型患者。
- 低pSUVmax(<8.75)、低SCC-Ag(<0.79 ng/mL)和低CYFRA21-1(<2.91 ng/mL)与EGFR突变显著相关,三者联合的AUC为0.754。
核心结论
- 低浓度的CYFRA21-1和SCC-Ag以及低pSUVmax与男性NSCLC患者的EGFR突变相关,这些因素联合可提高对EGFR突变状态的区分能力。
研究设计与样本
- 回顾性分析2019年10月至2022年3月间121例男性NSCLC患者,所有患者治疗前接受18F-FDG PET/CT并检测8种血清肿瘤标志物。
主要发现
- 39例(32.2%)患者检测到EGFR突变。
- EGFR突变患者血清CYFRA21-1浓度为2.65,野生型患者为4.01(P=0.002);EGFR突变患者血清SCC-Ag浓度为0.67,野生型患者为1.05(P=0.006)。
- 两组间CEA、NSE、CA 50、CA125、CA72-4和铁蛋白无显著差异。
- 低CYFRA21-1、低SCC-Ag、低pSUVmax及三者联合的ROC曲线下面积分别为0.679、0.655、0.685和0.754。
关键数值与推荐
- 低pSUVmax定义为<8.75,低血清SCC-Ag定义为<0.79 ng/mL,低CYFRA21-1定义为<2.91 ng/mL。
- 低CYFRA21-1、低SCC-Ag、低pSUVmax及三者联合的ROC曲线下面积分别为0.679、0.655、0.685和0.754。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on 18F-fluoro-2-deoxy-2-deoxyglucose (18F-FDG) PET/CT and serum tumor markers (STMs) to determine EGFR mutation status in male patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent 18F-FDG PET/CT scan before treatment and monitored 8 STMs (cytokeratin 19 fragment [CYFRA21-1], squamous cell carcinoma-related antigen [SCC-Ag], carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], carbohydrate antigen [CA] 50, CA125, CA72-4, and ferritin). A comparison was done between EGFR mutant and wild-type patients in terms of the maximum standardized uptake value of primary tumors (pSUVmax) and 8 STMs. We performed receiver operating characteristic (ROC) curve and multiple logistic regression analyses to determine predictors for EGFR mutation status. RESULTS: EGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUVmax (< 8.75), low serum SCC-Ag (< 0.79 ng/mL) and CYFRA21-1 (< 2.91 ng/mL) concentrations. The area under ROC curve values were 0.679, 0.655, 0.685 and 0.754, respectively, for low CYFRA21-1, SCC-Ag, pSUVmax and the combination of these three factors. CONCLUSIONS: We demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUVmax, were associated with EGFR mutations, and that the combination of these factors resulted in a higher differentiation of EGFR mutation status in male patients with NSCLC.
引用
- Jiang M, Chen P, Guo X, et al. Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res. 2023. PMID: 37014455. doi:10.1186/s13550-023-00976-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。